vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $30.1M, roughly 1.9× Dominari Holdings Inc.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -83.0% vs -438.1%, a 355.1% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 36.9%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 48.5%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
DOMH vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $57.3M |
| Net Profit | $-131.8M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -8.9% | -82.2% |
| Net Margin | -438.1% | -83.0% |
| Revenue YoY | 220.4% | 36.9% |
| Net Profit YoY | -12426.2% | -9.6% |
| EPS (diluted) | $-6.94 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $57.3M | ||
| Q3 25 | $50.8M | $51.3M | ||
| Q2 25 | $34.1M | $48.5M | ||
| Q1 25 | $8.1M | $32.7M | ||
| Q4 24 | $9.4M | $41.8M | ||
| Q3 24 | $4.0M | $33.3M | ||
| Q2 24 | $6.2M | $29.1M | ||
| Q1 24 | $1.4M | $26.0M |
| Q4 25 | $-131.8M | $-47.5M | ||
| Q3 25 | $125.2M | $-52.9M | ||
| Q2 25 | $16.6M | $-46.6M | ||
| Q1 25 | $-32.5M | $-49.5M | ||
| Q4 24 | $1.1M | $-43.3M | ||
| Q3 24 | $-4.2M | $-43.6M | ||
| Q2 24 | $-6.1M | $-32.3M | ||
| Q1 24 | $-5.4M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | -8.9% | -82.2% | ||
| Q3 25 | -3.1% | -102.6% | ||
| Q2 25 | -57.0% | -93.4% | ||
| Q1 25 | -394.6% | -143.7% | ||
| Q4 24 | 0.4% | -98.6% | ||
| Q3 24 | -79.1% | -132.0% | ||
| Q2 24 | -44.3% | -139.2% | ||
| Q1 24 | -205.2% | -538.7% |
| Q4 25 | -438.1% | -83.0% | ||
| Q3 25 | 246.4% | -103.1% | ||
| Q2 25 | 48.7% | -96.1% | ||
| Q1 25 | -400.5% | -151.4% | ||
| Q4 24 | 11.4% | -103.6% | ||
| Q3 24 | -104.2% | -131.2% | ||
| Q2 24 | -99.1% | -110.9% | ||
| Q1 24 | -398.0% | -544.4% |
| Q4 25 | $-6.94 | $-0.73 | ||
| Q3 25 | $7.27 | $-0.82 | ||
| Q2 25 | $1.12 | $-0.75 | ||
| Q1 25 | $-3.02 | $-0.81 | ||
| Q4 24 | $0.21 | $-0.71 | ||
| Q3 24 | $-0.67 | $-0.73 | ||
| Q2 24 | $-1.01 | $-0.55 | ||
| Q1 24 | $-0.91 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $139.1M |
| Total Assets | $112.9M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $388.9M | ||
| Q3 25 | $176.2M | $416.1M | ||
| Q2 25 | $28.2M | $291.0M | ||
| Q1 25 | $18.9M | $314.5M | ||
| Q4 24 | $8.2M | $320.6M | ||
| Q3 24 | $7.2M | $298.4M | ||
| Q2 24 | $12.1M | $319.1M | ||
| Q1 24 | $7.1M | $201.2M |
| Q4 25 | $69.4M | $139.1M | ||
| Q3 25 | $210.2M | $148.8M | ||
| Q2 25 | $88.6M | $-11.9M | ||
| Q1 25 | $42.4M | $18.9M | ||
| Q4 24 | $39.9M | $21.7M | ||
| Q3 24 | $38.3M | $11.2M | ||
| Q2 24 | $42.4M | $39.3M | ||
| Q1 24 | $47.7M | $61.6M |
| Q4 25 | $112.9M | $480.2M | ||
| Q3 25 | $223.4M | $506.9M | ||
| Q2 25 | $109.3M | $372.7M | ||
| Q1 25 | $52.3M | $386.7M | ||
| Q4 24 | $47.1M | $392.3M | ||
| Q3 24 | $43.4M | $363.6M | ||
| Q2 24 | $49.1M | $381.8M | ||
| Q1 24 | $52.2M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-25.4M | ||
| Q3 25 | $-4.9M | $-26.6M | ||
| Q2 25 | $-353.0K | $-23.3M | ||
| Q1 25 | $1.2M | $-40.4M | ||
| Q4 24 | $-16.7M | $-18.8M | ||
| Q3 24 | $-4.7M | $-25.2M | ||
| Q2 24 | $1.4M | $-29.1M | ||
| Q1 24 | $-8.6M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
RYTM
Segment breakdown not available.
